Schott Supports Russia’s ‘Pharma 2030’ Strategy

As part of a main global investment incentive, Schott has invested in high-speed machines at the Russian site Zavolzhye.Up to 40 jobs will be created with the nearly €10m investment. Schott Russia relies on the latest technology according to international standards. Frank Bellemans VP Global Operations within the Business Unit Pharmaceutical Systems at Schott, said, "The glass packaging will even get better and safer. In addition, the production will get more energy-efficient".

Schott has again renewed its commitment to Russia for marking the 10th anniversary of its Zavolzhye manufacturing site. Site Manager Denis Nikitin said: "The move will further enable an even stronger integration into the global Schott production network. It will support our joint fight against COVID and the secure supply to our Russian customers. It will also strengthen the production ability in the spirit of the current Russian ‘Pharma 2030’ strategy." The Russian government aims to encourage the development of drugs and their production while seizing export opportunities with this strategy. Local access to high-quality packaging is crucial to reach this goal.

“Our intention is to keep working closely with the Russian pharma industry and support their growth plans by offering just the right packaging solutions," said Denis Nikitin. The site manufactures vials and ampoules made of borosilicate glass and serves the pharma industry to safely package, transport, and store medications.

Schott works with the industry on the development of future-oriented packaging solutions. These include a range of ultra-pure pharmaceutical vials to meet the exacting drug stability needs of low-fill drugs and the iQ ready-to-use concept for aseptic filling of medications. Designed as a modular concept, Schott Everic enables pharmaceutical companies to package biologic drugs while supporting today's quality requirements of fill and finish lines.